The current in-vivo data supports the potential relevance of volasertib as a therapeutic adjunct through marked inhibition of tumor growth alone and in conjunction with TMZ and corresponding decreases in expression of stem cell markers (survivin and CD133) and increased detection of DNA damage (gH2AX) and apoptosis (tunel, cleaved caspase-3). Here, PROM1 is linked to neoplasm.